Porous Silicon Particle-Assisted
Mass Spectrometry
Technology Unlocks Serum Metabolic Fingerprints in the Progression
From Chronic Hepatitis B to Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common malignancy
and generally
develops from liver cirrhosis (LC), which is primarily caused by the
chronic hepatitis B (CHB) virus. Reliable liquid biopsy methods for
HCC screening in high-risk populations are urgently needed. Here,
we establish a porous silicon-assisted laser desorption ionization
mass spectrometry (PSALDI-MS) technology to profile metabolite information
hidden in human serum in a high throughput manner. Serum metabolites
can be captured in the pore channel of APTES-modified porous silicon
(pSi) particles and well-preserved during storage or transportation.
Furthermore, serum metabolites captured in the APTES-pSi particles
can be directly detected on the LDI-MS without the addition of an
organic matrix, thus greatly accelerating the acquisition of metabolic
fingerprints of serum samples. The PSALDI-MS displays the capability
of high throughput (5 min per 96 samples), high reproducibility (coefficient
of variation <15%), high sensitivity (LOD ∼ 1 pmol), and
high tolerance to background salt and proteins. In a multicenter cohort
study, 1433 subjects including healthy controls (HC), CHB, LC, and
HCC volunteers were enrolled and nontargeted serum metabolomic analysis
was performed on the PSALDI-MS platform. After the selection of feature
metabolites, a stepwise diagnostic model for the classification of
different liver disease stages was constructed by the machine learning
algorithm. In external testing, the accuracy of 91.2% for HC, 71.4%
for CHB, 70.0% for LC, and 95.3% for HCC was achieved by chemometrics.
Preliminary studies indicated that the diagnostic model constructed
from serum metabolic fingerprint also displays good predictive performance
in a prospective observation. We believe that the combination of PSALDI-MS
technology and machine learning may serve as an efficient tool in
clinical practice.